semaglutide bowel obstruction class action in louisiana The GLP-1 RA Legal Timeline: How Serious Side Effects Led to Multidistrict Litigation Chynthia Bromley | The Farmacy

Furberg, A

Unlike semaglutide and tirzepatide (which could be compounded during shortages), retatrutide has never been FDA-approved

Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare beneficiaries to receive certain GLP-1 weight-loss medications for $50 per month

Potential Side Effects Although both peptides are well-tolerated, some patients may experience: Mild water retention Joint stiffness (temporary) Insulin sensitivity changes (rare) Injection site irritation Patients should always be monitored by a physician trained in peptide therapy, and adjustments can be made to dose or frequency to mitigate any issues